NGEN News

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma to Participate at Upcoming Investor Conferences

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury